Nasdaq vktx.

Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. …Viking Therapeutics, Inc. (NASDAQ:VKTX) is an American biotechnology company headquartered in San Diego, California. It develops drugs for patients suffering from surgical complications and liver ...Viking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...VKTX Latest Pre Market Trades · Trending Stocks · Your symbols have been updated · Edit Watchlist · Opt in to Smart Portfolio · Privacy Preference Center. When ...Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX -2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares ...

In the news. Yahoo Finance. 3 days ago. Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease. With ...Dec 1, 2023 · In the previous quarter, Viking Therapeutics (NASDAQ:VKTX) missed the analysts' consensus estimate of ($0.22) by $0.01 with a reported earnings per share (EPS) of ($0.23). Learn more on analysts' earnings estimate vs. VKTX's actual earnings.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is up about 315% over the past one year. Viking Therapeutics, Inc. (NASDAQ:VKTX) in July filed for a mixed securities shelf offering.

Viking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...LL28. The last time I spoke about Viking Therapeutics, Inc. (NASDAQ:VKTX), I talked about its progress in advancing its drug VK2809 for the treatment of patients with non-alcoholic steatohepatitis ...VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... Pfizer (NYSE:PFE) shares hit a new 52-week low on Friday after announcing that its twice-daily oral weight loss candidate danuglipron will not reach late-stage development as a Phase 2 readout ...

Viking Therapeutics (VKTX 6.46%) seeks to develop new treatments for metabolic and endocrine diseases. Lead drug candidate VK-2809 recently entered a phase 2b clinical trial at the end of last ...

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.

Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ... 02 Feb, 2018, 08:33 ET. SAN DIEGO, Feb. 2, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel ...During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 1.77 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $12.22, reflecting an intraday gain of 3.30% or $0.39. The 52-week high for the VKTX share is $ ...VKTX Latest Pre Market Trades · Trending Stocks · Your symbols have been updated · Edit Watchlist · Opt in to Smart Portfolio · Privacy Preference Center. When ...Nasdaq Futures. 15,979.75 ... (NASDAQ:VKTX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the …Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ...

SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...As at June 2022, Viking Therapeutics had cash of US$169m and no debt. In the last year, its cash burn was US$47m. So it had a cash runway of about 3.6 years from June 2022. There's no doubt that ...Dec 15, 2019 · Of the funds tracked by Insider Monkey, Peter S. Park's Park West Asset Management has the largest position in Viking Therapeutics, Inc. (NASDAQ:VKTX), worth close to $12 million, accounting for 0 ... Rhumbline Advisers acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,829 shares of the biotechnology company’s stock, valued at approximately $2,072,000. Rhumbline …SAN DIEGO, Oct. 23, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Viking Therapeutics Inc (NASDAQ:VKTX) Viking Therapeutics Inc. 13.01. Delayed Data. As of Dec 01. +0.79 / +6.42%. Today’s Change. 3.54. Today ||| 52-Week Range.

About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. See Also. Nasdaq MarketSIte. Do Not Sell …Jan 24, 2022 · What happenedInvestors didn't exactly launch a raid on Viking Therapeutics (NASDAQ: VKTX) stock during Monday's trading session. The shares tumbled by nearly 7% on the back of discouraging news ...

Mar 29, 2023 · Shares of Viking Therapeutics VKTX have surged almost 70% on Mar 28, after it announced positive clinical data of VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose ... (NASDAQ: VKTX) Viking Therapeutics's 52-week high was $25.72, and its 52-week low was $3.54. It is currently -49.42% from its 52-week high and 267.51% from its ...Fintel reports that on May 16, 2023, BTIG maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 35.91% Upside. As of May 11, 2023 ...Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the …View real-time VKTX stock price and news, ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with volume of at least 50,000.During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 1.77 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $12.22, reflecting an intraday gain of 3.30% or $0.39. The 52-week high for the VKTX share is $ ...Financial News. View the latest Viking Therapeutics Inc. (VKTX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

May 16, 2023 · Adds background on NASH and details on the study throughout. May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial ...

Viking Therapeutics Inc (NASDAQ:VKTX) Viking Therapeutics Inc. 13.01. Delayed Data. As of Dec 01. +0.79 / +6.42%. Today’s Change. 3.54. Today ||| 52-Week Range.SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Oct 25, 2023Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share. All thanks to its potential treatment for obesity, VK2735.Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.The latest price target for Viking Therapeutics ( NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023. The analyst firm set a price target for 32.00 expecting VKTX to rise ...Mar 16, 2023 · Shares of Viking Therapeutics (NASDAQ: VKTX) are trading down over 15% late into Tuesday's session, in a move linked to the disappointing clinical data posted by VKTX's competitor Altimmune, Inc ... Stock Ratings Screener · Free Ratings Newsletter. This page (NASDAQ:VKTX) was last updated on 12/4/2023 by ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Nasdaq Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access ...(NASDAQ: VKTX) Viking Therapeutics's 52-week high was $25.72, and its 52-week low was $3.54. It is currently -49.42% from its 52-week high and 267.51% from its ...Stock analysis for Viking Therapeutics Inc (VKTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Based on analysts offering 12 month price targets for VKTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Oct 25, 2023SAN DIEGO, April 11, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Instagram:https://instagram. bridgewater stockhigh yield savings account vs roth irapenny stocks that pay dividendsvenezuela etf So, the natural question for Viking Therapeutics (NASDAQ:VKTX) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual ...02 Feb, 2018, 08:33 ET. SAN DIEGO, Feb. 2, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel ... wmcp designationschwab private client services Trending Stocks AMZN Amazon.com, Inc. Common Stock $105.11 -0.34 0.32% TSLA Tesla, Inc. Common Stock $164.04 -0.27 0.16% FRC FIRST REPUBLIC … stock banks LL28. The last time I spoke about Viking Therapeutics, Inc. (NASDAQ:VKTX), I talked about its progress in advancing its drug VK2809 for the treatment of patients with non-alcoholic steatohepatitis ...Fiscal Q3 2023 ended 9/30/23. Reported on 10/25/23. Get the latest Viking Therapeutics Inc (VKTX) real-time quote, historical performance, charts, and other financial information to …NASDAQ:VKTX Viking Therapeutics (VKTX) Stock Forecast & Price Target $11.56 +0.21 (+1.85%) (As of 11/22/2023 ET) Compare Today's Range $11.21 $11.68 50 …